ATEZOLIZUMAB
atezolizumab 840 mg/14 mL injection, 14 mL vial
ATEZOLIZUMAB (12174R)
12174R
Manner of administration:Injection
Restriction 10972
Indication: Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular
carcinoma
Treatment phase: Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1680 mg | # of repeats: 5 | DPMA: $9,537.53 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Tecentriq
(atezolizumab 840 mg/14 mL injection, 14 mL vial)
|
||||
